



FEP Medical Policy Manual

FEP 7.01.123 Plugs for Anal Fistula Repair

Effective Policy Date: April 1, 2021

Related Policies:

Original Policy Date: December 2011

None

Plugs for Anal Fistula Repair

Description

Description

Anal fistula plugs (AFPs) are biosynthetic devices used to promote healing and prevent the recurrence of anal fistulas. They are proposed as an alternative to procedures including fistulotomy, endorectal advancement flaps, seton drain placement, and use of fibrin glue in the treatment of anal fistulas.

OBJECTIVE

The objective of this evidence review is to determine whether the use of anal fistula plugs improves the net health outcome for anal fistulas compared with other approaches.

The policies contained in the FEP Medical Policy Manual are developed to assist in administering contractual benefits and do not constitute medical advice. They are not intended to replace or substitute for the independent medical judgment of a practitioner or other health care professional in the treatment of an individual member. The Blue Cross and Blue Shield Association does not intend by the FEP Medical Policy Manual, or by any particular medical policy, to recommend, advocate, encourage or discourage any particular medical technologies. Medical decisions relative to medical technologies are to be made strictly by members/patients in consultation with their health care providers. The conclusion that a particular service or supply is medically necessary does not constitute a representation or warranty that the Blue Cross and Blue Shield Service Benefit Plan covers (or pays for) this service or supply for a particular member.

POLICY STATEMENT

Biosynthetic fistula plugs, including plugs made of porcine small intestine submucosa or of synthetic material, are considered **investigational** for the repair of anal fistulas.

POLICY GUIDELINES

None

BENEFIT APPLICATION

Experimental or investigational procedures, treatments, drugs, or devices are not covered (See General Exclusion Section of brochure).

FDA REGULATORY STATUS

Several plugs for anal fistula repair have been cleared for marketing by the FDA through the 510(k) process and are outlined in Table 1.

Table 1. Devices for Anal Fistula Repair

Device	Year	Description	Indication(s)	Predicate Device(s)	FDA Product Code
SIS Fistula Plug (Cook Biotech)	Mar 2005	<ul style="list-style-type: none"> Manufactured from porcine SIS 	<ul style="list-style-type: none"> Repair of anal, rectal, and enterocutaneous fistulas 	<ul style="list-style-type: none"> Surgisis Soft Tissue Graft (Cook Biotech) Stratasis Urethral Sling (Cook Biotech) 	FTM
Surgisis RVP Recto-Vaginal Fistula Plug (Cook Biotech)	Oct 2006	<ul style="list-style-type: none"> Manufactured from porcine SIS Tapered configuration with a button to increase plug retention and improve fistula blockage 	<ul style="list-style-type: none"> Reinforce soft tissue to repair rectovaginal fistulas 	<ul style="list-style-type: none"> SIS Fistula Plug (Cook Biotech) 	FTM
Surgisis Biodesign Enterocutaneous Fistula Plug (Cook Biotech)	Feb 2009	<ul style="list-style-type: none"> Manufactured from porcine SIS Tapered configuration with flange to increase plug retention and improve fistula blockage 	<ul style="list-style-type: none"> Reinforce soft tissue to repair enterocutaneous fistulas 	<ul style="list-style-type: none"> SIS Fistula Plug (Cook Biotech) 	FTM

The policies contained in the FEP Medical Policy Manual are developed to assist in administering contractual benefits and do not constitute medical advice. They are not intended to replace or substitute for the independent medical judgment of a practitioner or other health care professional in the treatment of an individual member. The Blue Cross and Blue Shield Association does not intend by the FEP Medical Policy Manual, or by any particular medical policy, to recommend, advocate, encourage or discourage any particular medical technologies. Medical decisions relative to medical technologies are to be made strictly by members/patients in consultation with their health care providers. The conclusion that a particular service or supply is medically necessary does not constitute a representation or warranty that the Blue Cross and Blue Shield Service Benefit Plan covers (or pays for) this service or supply for a particular member.

Gore Bio-A Fistula Plug (W.L. Gore & Associates)	Mar 2009	<ul style="list-style-type: none"> Manufactured from bioabsorbable PGA:TMC copolymer Supplied in a 3-dimensional configuration of a disk with attached tubes 	<ul style="list-style-type: none"> Reinforce soft tissue to repair anorectal fistulas 	<ul style="list-style-type: none"> Gore Bioabsorbable Mesh (W.L. Gore & Associates) SIS Fistula Plug (Cook Biotech) 	FTL
Biodesign Anal Fistula Plug (Cook Biotech)	May 2016	<ul style="list-style-type: none"> Manufactured from porcine SIS Additional wash steps added in processing 	<ul style="list-style-type: none"> Reinforce soft tissue where a rolled configuration is required to repair anal, rectal, and enterocutaneous fistulas 	<ul style="list-style-type: none"> SIS Fistula Plug (Cook Biotech) 	FTM

FDA: U.S. Food and Drug Administration; PGA:TMC: polyglycolide-co-trimethylene carbonate; SIS: small intestinal submucosa.

RATIONALE

Summary of Evidence

For individuals who have anal fistula(s) who receive placement of anal fistula plugs (AFP(s)), the evidence includes 4 randomized controlled trials (RCTs), a number of comparative and noncomparative nonrandomized studies, and systematic reviews of these studies. Relevant outcomes are symptoms, change in disease status, morbid events, functional outcomes, and treatment-related morbidity. Two RCTs comparing AFP with surgical flap treatment have reported disparate findings: one found significantly higher rates of fistula recurrence with AFP; the other found similar rates of recurrence for AFP and surgical treatment. Another RCT that compared AFP with seton drain removal alone for patients with fistulizing Crohn disease, found no significant difference in healing rates at 12 weeks between groups. An RCT comparing AFP with surgeon's preference reported significantly higher complication rates with AFP. Systematic reviews of AFP repair have demonstrated a wide range of success rates and heterogeneity in study results. Nonrandomized studies have also reported conflicting results. The evidence is insufficient to determine the effects of the technology on health outcomes.

SUPPLEMENTAL INFORMATION

Practice Guidelines and Position Statements

American Society of Colon and Rectal Surgeons

The 2016 practice guidelines on the treatment of anorectal abscess, fistula-in-ano, and rectovaginal fistula from the Society provided a weak recommendation with moderate-quality evidence.²³ With recent evidence of success rates of less than 50% in most studies for the treatment of complex anal fistulas with an anal fistula plug, the guidelines concluded that the fistula plug is relatively ineffective in the treatment of fistula-in-ano.

The policies contained in the FEP Medical Policy Manual are developed to assist in administering contractual benefits and do not constitute medical advice. They are not intended to replace or substitute for the independent medical judgment of a practitioner or other health care professional in the treatment of an individual member. The Blue Cross and Blue Shield Association does not intend by the FEP Medical Policy Manual, or by any particular medical policy, to recommend, advocate, encourage or discourage any particular medical technologies. Medical decisions relative to medical technologies are to be made strictly by members/patients in consultation with their health care providers. The conclusion that a particular service or supply is medically necessary does not constitute a representation or warranty that the Blue Cross and Blue Shield Service Benefit Plan covers (or pays for) this service or supply for a particular member.

National Institute for Health and Care Excellence

In 2019, the National Institute for Health and Care Excellence updated its guidance on the suturable bioprosthetic plug.²⁴ The Institute determined that "evidence on the safety and efficacy of bioprosthetic plug insertion for anal fistula is adequate to support the use of this procedure provided that standard arrangements are in place for clinical governance, consent, and audit." Though, it was noted that "the procedure should only be done by a surgeon experienced in managing anal fistulas."

U.S. Preventive Services Task Force Recommendations

Not applicable.

Medicare National Coverage

There is no national coverage determination. In the absence of a national coverage determination, coverage decisions are left to the discretion of local Medicare carriers.

REFERENCES

1. Simpson JA, Banerjee A, Scholefield JH. Management of anal fistula. *BMJ*. Oct 15 2012; 345: e6705. PMID 23069597
2. Campbell ML, Abboud EC, Dolberg ME, et al. Treatment of refractory perianal fistulas with ligation of the intersphincteric fistula tract: preliminary results. *Am Surg*. Jul 2013; 79(7): 723-7. PMID 23816007
3. Ozturk E. Treatment of recurrent anal fistula using an autologous cartilage plug: a pilot study. *Tech Coloproctol*. May 2015; 19(5): 301-7. PMID 25850629
4. Narang SK, Jones C, Alam NN, et al. Delayed absorbable synthetic plug (GORE(R) BIO-A(R)) for the treatment of fistula-in-ano: a systematic review. *Colorectal Dis*. Jan 2016; 18(1): 37-44. PMID 26542191
5. Nasser Y, Cassella L, Berns M, et al. The anal fistula plug in Crohn's disease patients with fistula-in-ano: a systematic review. *Colorectal Dis*. Apr 2016; 18(4): 351-6. PMID 26749385
6. Xu Y, Tang W. Comparison of an anal fistula plug and mucosa advancement flap for complex anal fistulas: a meta-analysis. *ANZ J Surg*. Dec 2016; 86(12): 978-982. PMID 27680894
7. Cirocchi R, Trastulli S, Morelli U, et al. The treatment of anal fistulas with biologically derived products: is innovation better than conventional surgical treatment? An update. *Tech Coloproctol*. Jun 2013; 17(3): 259-73. PMID 23207714
8. van Koperen PJ, Bemelman WA, Gerhards MF, et al. The anal fistula plug treatment compared with the mucosal advancement flap for cryptoglandular high transsphincteric perianal fistula: a double-blinded multicenter randomized trial. *Dis Colon Rectum*. Apr 2011; 54(4): 387-93. PMID 21383557
9. Ortiz H, Marzo J, Ciga MA, et al. Randomized clinical trial of anal fistula plug versus endorectal advancement flap for the treatment of high cryptoglandular fistula in ano. *Br J Surg*. Jun 2009; 96(6): 608-12. PMID 19402190
10. Pu YW, Xing CG, Khan I, et al. Fistula plug versus conventional surgical treatment for anal fistulas. A system review and meta-analysis. *Saudi Med J*. Sep 2012; 33(9): 962-6. PMID 22964807
11. Leng Q, Jin HY. Anal fistula plug vs mucosa advancement flap in complex fistula-in-ano: A meta-analysis. *World J Gastrointest Surg*. Nov 27 2012; 4(11): 256-61. PMID 23494149
12. O'Riordan JM, Datta I, Johnston C, et al. A systematic review of the anal fistula plug for patients with Crohn's and non-Crohn's related fistula-in-ano. *Dis Colon Rectum*. Mar 2012; 55(3): 351-8. PMID 22469804
13. Garg P, Song J, Bhatia A, et al. The efficacy of anal fistula plug in fistula-in-ano: a systematic review. *Colorectal Dis*. Oct 2010; 12(10): 965-70. PMID 19438881
14. Jacob TJ, Perakath B, Keighley MR. Surgical intervention for anorectal fistula. *Cochrane Database Syst Rev*. May 12 2010; (5): CD006319. PMID 20464741
15. Jayne DG, Scholefield J, Tolan D, et al. A Multicenter Randomized Controlled Trial Comparing Safety, Efficacy, and Cost-effectiveness of the Surgisis Anal Fistula Plug Versus Surgeon's Preference for Transsphincteric Fistula-in-Ano: The FIAT Trial. *Ann Surg*. Jun 09 2020. PMID 32516229
16. Senejoux A, Siproudhis L, Abramowitz L, et al. Fistula Plug in Fistulising Ano-Perineal Crohn's Disease: a Randomised Controlled Trial. *J Crohns Colitis*. Feb 2016; 10(2): 141-8. PMID 26351393

The policies contained in the FEP Medical Policy Manual are developed to assist in administering contractual benefits and do not constitute medical advice. They are not intended to replace or substitute for the independent medical judgment of a practitioner or other health care professional in the treatment of an individual member. The Blue Cross and Blue Shield Association does not intend by the FEP Medical Policy Manual, or by any particular medical policy, to recommend, advocate, encourage or discourage any particular medical technologies. Medical decisions relative to medical technologies are to be made strictly by members/patients in consultation with their health care providers. The conclusion that a particular service or supply is medically necessary does not constitute a representation or warranty that the Blue Cross and Blue Shield Service Benefit Plan covers (or pays for) this service or supply for a particular member.

17. Hall JF, Bordeianou L, Hyman N, et al. Outcomes after operations for anal fistula: results of a prospective, multicenter, regional study. *Dis Colon Rectum*. Nov 2014; 57(11): 1304-8. PMID 25285698
18. Hyman N, O'Brien S, Osler T. Outcomes after fistulotomy: results of a prospective, multicenter regional study. *Dis Colon Rectum*. Dec 2009; 52(12): 2022-7. PMID 19934925
19. Fisher OM, Raptis DA, Vetter D, et al. An outcome and cost analysis of anal fistula plug insertion vs endorectal advancement flap for complex anal fistulae. *Colorectal Dis*. Jul 2015; 17(7): 619-26. PMID 25641401
20. Christoforidis D, Pieh MC, Madoff RD, et al. Treatment of transsphincteric anal fistulas by endorectal advancement flap or collagen fistula plug: a comparative study. *Dis Colon Rectum*. Jan 2009; 52(1): 18-22. PMID 19273951
21. Wang JY, Garcia-Aguilar J, Sternberg JA, et al. Treatment of transsphincteric anal fistulas: are fistula plugs an acceptable alternative?. *Dis Colon Rectum*. Apr 2009; 52(4): 692-7. PMID 19404076
22. Chung W, Kazemi P, Ko D, et al. Anal fistula plug and fibrin glue versus conventional treatment in repair of complex anal fistulas. *Am J Surg*. May 2009; 197(5): 604-8. PMID 19393353
23. Vogel JD, Johnson EK, Morris AM, et al. Clinical Practice Guideline for the Management of Anorectal Abscess, Fistula-in-Ano, and Rectovaginal Fistula. *Dis Colon Rectum*. Dec 2016; 59(12): 1117-1133. PMID 27824697
24. National Institute for Health and Care Excellence (NICE). Bioprosthetic plug insertion for anal fistula [IPG662]. September 25, 2019; <https://www.nice.org.uk/guidance/ipg662>. Accessed October 2, 2020.

POLICY HISTORY - THIS POLICY WAS APPROVED BY THE FEP® PHARMACY AND MEDICAL POLICY COMMITTEE ACCORDING TO THE HISTORY BELOW:

Date	Action	Description
December 2011	New policy	
December 2012	Replace policy	Literature review update, Rationale and references updated, Policy statement unchanged.
December 2013	Replace policy	Policy updated with literature review. References 1-3 added. No change to policy statement
December 2014	Replace policy	Policy updated with literature review. References 1-3 and 15-17 added. Rationale and background sections revised. Policy statement unchanged.
December 2015	Replace policy	Policy updated with literature review through July 30, 2015; references 13-14 and 18 added. Policy statement changed to clarify that the policy refers to anal fistulas. Title of policy changed to "Plugs for Anal Fistula Repair."
March 2017	Replace policy	Policy updated with literature review; references 4-6 and 13 added. Policy statement changed from not medically necessary to investigational.
March 2018	Replace policy	Policy updated with literature review through September 19, 2017; reference 24 added; reference 25 updated. Policy statement unchanged.
March 2019	Replace policy	Policy updated with literature review through September 6, 2018; reference 24 added. Policy statement unchanged.

The policies contained in the FEP Medical Policy Manual are developed to assist in administering contractual benefits and do not constitute medical advice. They are not intended to replace or substitute for the independent medical judgment of a practitioner or other health care professional in the treatment of an individual member. The Blue Cross and Blue Shield Association does not intend by the FEP Medical Policy Manual, or by any particular medical policy, to recommend, advocate, encourage or discourage any particular medical technologies. Medical decisions relative to medical technologies are to be made strictly by members/patients in consultation with their health care providers. The conclusion that a particular service or supply is medically necessary does not constitute a representation or warranty that the Blue Cross and Blue Shield Service Benefit Plan covers (or pays for) this service or supply for a particular member.

Date	Action	Description
March 2020	Replace policy	Policy updated with literature review through September 6, 2019; reference on NICE updated. Policy statement unchanged.
March 2021	Replace policy	Policy updated with literature review through August 20, 2020; reference added. Policy statement unchanged.

The policies contained in the FEP Medical Policy Manual are developed to assist in administering contractual benefits and do not constitute medical advice. They are not intended to replace or substitute for the independent medical judgment of a practitioner or other health care professional in the treatment of an individual member. The Blue Cross and Blue Shield Association does not intend by the FEP Medical Policy Manual, or by any particular medical policy, to recommend, advocate, encourage or discourage any particular medical technologies. Medical decisions relative to medical technologies are to be made strictly by members/patients in consultation with their health care providers. The conclusion that a particular service or supply is medically necessary does not constitute a representation or warranty that the Blue Cross and Blue Shield Service Benefit Plan covers (or pays for) this service or supply for a particular member.